tipifarnib has been researched along with carbostyril in 279 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (carbostyril) | Trials (carbostyril) | Recent Studies (post-2010) (carbostyril) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 12,855 | 1,323 | 5,611 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.36) | 18.2507 |
| 2000's | 191 (68.46) | 29.6817 |
| 2010's | 72 (25.81) | 24.3611 |
| 2020's | 15 (5.38) | 2.80 |
| Authors | Studies |
|---|---|
| Blatner, GL; Cheson, BD; Wright, J | 1 |
| Belly, RT; Bol, CJ; Bowden, C; Chiao, J; Chow, C; Cowan, KH; End, DW; Gress, RE; Hakim, FT; Horak, ID; Kohler, DR; Kopp, WC; Kremer, AB; Larkin, G; Noone, M; Nussenblatt, RB; Piotrovsky, VK; Todd, A; Woestenborghs, R; Zujewski, J | 1 |
| Angibaud, P; Applegate, TL; Bowden, C; Devine, A; End, DW; Fuery, CJ; Poignet, H; Sanz, G; Skrzat, S; Smets, G; Todd, AV; Venet, M; Wouters, W | 1 |
| Beloueche, M; Jackson, LE; Leach, MO; Ronen, SM | 1 |
| Bol, CJ; Punt, CJ; Seifert, WF; van Maanen, L; Wagener, DJ | 1 |
| Ange, D; Belly, RT; Bol, K; Buddharaju, L; End, DW; Gojo, I; Highsmith, WE; Hohl, RJ; Horak, I; Karp, JE; Kaufmann, SH; Kottke, TJ; Lancet, JE; Liesveld, J; Rosenblatt, J; Rybak, ME; Thibault, A; Tidwell, ML; Wright, JJ | 1 |
| Gabrilove, JL | 1 |
| Karp, JE | 2 |
| Adjei, AA; End, DW; Karp, JE; Kaufmann, SH; Lancet, JE; Wright, JJ | 1 |
| Clarke, PA; Detre, S; Dowsett, M; End, D; Howes, AJ; Johnston, SR; Kelland, LR; Patterson, L; Smith, V; Valenti, M; Workman, P | 1 |
| Bernhard, E; Hahn, SM; McKenna, WG | 1 |
| Jiang, C; Kato-Stankiewicz, J; Machado, I; Tamanoi, F; Thapar, N | 1 |
| Andela, VB; O'Keefe, RJ; Puzas, EJ; Rosenblatt, JD; Rosier, RN; Schwarz, EM | 1 |
| Norman, P | 1 |
| Beijnen, JH; Boerrigter, L; Bol, CJ; Crul, M; de Gast, GC; de Jong, D; de Klerk, GJ; Palmer, PA; Schellens, JH; Swart, M; Tan, H; van't Veer, LJ | 1 |
| Barrie, E; Kelland, LR; Rowlands, MG; Smith, V; Workman, P | 1 |
| Calam, A; Garner, JV; Garner, RC; Goris, I; Gregory, S; Laenen, AA; Leong, D; Meuldermans, W; Snel, CA; Vanhoutte, E; Whattam, M | 1 |
| Bonnet, J; Cohen-Jonathan, E; Delmas, C; End, D; Favre, G; Heliez, C; Toulas, C | 1 |
| Cheson, BD; Gravell, AE; Wright, JJ; Zerivitz, K | 1 |
| Adjei, AA; Dy, GK; Haluska, P | 1 |
| Sánchez De Cos Escuín, J | 1 |
| Amiot, M; Bataille, R; Harousseau, JL; Le Gouill, S; Pellat-Deceunynck, C; Rapp, MJ; Robillard, N | 1 |
| Dancey, JE | 1 |
| Caponigro, F | 1 |
| Albitar, M; Cortes, J; Garcia-Manero, G; Giles, F; Kantarjian, H; Koller, C; Kurzrock, R; O'Brien, S; Rackoff, W; Talpaz, M; Thibault, A; Thomas, D | 1 |
| Adjei, AA; Dy, GK | 1 |
| Bonginelli, P; Capaccetti, B; Fanelli, M; Gasparini, G; Gattuso, D; Longo, R; Sarmiento, R | 1 |
| Smit, EF | 1 |
| Heinemann, V | 1 |
| Baum, C; Kirschmeier, P | 1 |
| Kelland, LR | 1 |
| Li, T; Sparano, JA | 1 |
| Abbruzzese, JL; Alpaugh, RK; Beard, M; Cohen, SJ; Ho, L; Hudes, GR; Lewis, NL; McLaughlin, S; Meropol, NJ; Perez-Ruixo, JJ; Ranganathan, S; Rogatko, A; Thistle, AM; Verhaeghe, T; Wang, H; Weiner, LM; Wright, JJ | 1 |
| Angibaud, P; Bourdrez, X; Devine, A; End, DW; Freyne, E; Ligny, Y; Mannens, G; Muller, P; Pilatte, I; Poncelet, V; Skrzat, S; Smets, G; Van Dun, J; Van Remoortere, P; Venet, M; Wouters, W | 1 |
| Nishiyama, M; Tahara, E; Tsuruo, T; Yasui, W | 1 |
| Adjei, AA; Bruzek, L; Erlichman, C; Geyer, S; Hanson, LJ; Hillman, S; Kaufmann, SH; Marks, RS; Mauer, A; Vokes, EE; Wright, JJ | 1 |
| End, DW; Gunning, WT; Kramer, PM; Lubet, RA; Pereira, MA; Steele, VE; Wouters, W | 1 |
| Gray, LA; Kaufmann, SH; Mesa, RA; Reeder, T; Schroeder, G; Tefferi, A | 1 |
| Angibaud, P; End, D; Venet, M | 1 |
| Karp, JE; Lancet, JE | 2 |
| Abrams, RA; Regine, WF; Rich, TA; Safran, H; Willett, CG | 1 |
| Dowsett, M; Ellis, P; Hickish, T; Houston, S; Howes, A; Johnston, SR; Kelland, L; Michiels, B; Palmer, P; Perez-Ruixo, JJ; Salter, J | 1 |
| Ashihara, E; Fuchida, S; Fujita, N; Inaba, T; Matsubara, H; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Bruzek, LM; Croghan, GA; Erlichman, C; Goldberg, RM; Hanson, LJ; Kaufmann, SH; Marks, RS; Palmer, PA; Pitot, HC; Reid, JM; Sloan, JA; Thibault, A | 1 |
| Cortes, JE; Freireich, EJ; Kantarjian, HM; Kurzrock, R; Sebti, SM; Singhania, N; Talpaz, M; Thomas, DA; Wilson, EF; Wright, JJ | 1 |
| Abboud, CN; Lancet, JE; Liesveld, JL; Lu, C; McNair, C; Menon, A; Rosell, KE; Rosenblatt, JD | 1 |
| Cortes, J | 2 |
| Eckhardt, SG; Gentner, L; Goetz, A; Hammond, LA; Izbicka, E; McCreery, H; Mori, M; Patnaik, A; Richards, H; Rowinsky, EK; Rybak, ME; Schwartz, G; Takimoto, CH; Terada, K; Tolcher, AA; Zhang, S | 1 |
| de Bono, JS; Rowinsky, EK; Tolcher, AW | 1 |
| Khuri, FR | 1 |
| Angibaud, P; Bourdrez, X; End, DW; Freyne, E; Lezouret, P; Mannens, G; Mevellec, L; Meyer, C; Pilatte, I; Poncelet, V; Roux, B; Saha, AK; Smets, G; Van Dun, J; Venet, M; Wouters, W | 1 |
| Angibaud, P; Bourdrez, X; Damsch, S; End, DW; Freyne, E; Janicot, M; Lezouret, P; Ligny, Y; Mannens, G; Mevellec, L; Meyer, C; Muller, P; Pilatte, I; Poncelet, V; Roux, B; Smets, G; Van Dun, J; Van Remoortere, P; Venet, M; Wouters, W | 1 |
| Cohen-Jonathan, E; Delmas, C; End, D; Favre, G; Rochaix, P; Toulas, C | 1 |
| Adjei, AA; Ahmann, G; Alsina, M; Belle, AN; Bruzek, LM; Cantor, AB; Dalton, WS; Djulbegovic, B; Fonseca, R; Gerbino, E; Greipp, PR; Kaufmann, SH; Overton, RM; Price-Troska, T; Sebti, SM; Sullivan, D; Wilson, EF; Wright, JJ | 1 |
| Alpaugh, RK; Cohen, SJ; Gallo, J; Gentner, L; Lewis, NL; Meropol, NJ; Palmer, PA; Rogatko, A; Schol, J; Verhaeghe, T; Weiner, LM; Yeslow, G; Zannikos, P | 1 |
| Beaupre, DM; Boise, LH; Cepero, E; Lichtenheld, MG; Obeng, EA | 1 |
| Tauchi, T | 1 |
| Albitar, M; Cortes, JE; De Porre, P; Estey, EH; Faderl, SH; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Kurzrock, R; Ryback, ME; Thibault, A; Thomas, DA | 1 |
| de Bruijn, P; de Heus, G; de Jonge, MJ; Eskens, FA; Kehrer, DF; Klaren, A; Mathijssen, RH; Palmer, PA; Planting, AS; Sparreboom, A; Verhaeghe, T; Verheij, C; Verweij, J; Xie, R; Zhang, S | 1 |
| Humblet, Y; Karasek, P; Ma, Y; Neumann, H; Oettle, H; Perez Ruixo, J; Post, S; Safran, H; Schoffski, P; Szawlowski, A; Van Cutsem, E; van de Velde, H; Verslype, C; Vervenne, WL; Von Hoff, D | 1 |
| Marsh, S; Mathijssen, RH; McLeod, HL; Sparreboom, A; Verweij, J | 1 |
| Beese, LS; Reid, TS | 1 |
| Heymach, JV; Johnson, BE | 1 |
| Cornelissen, B; Dierckx, RA; Kersemans, V; Lahorte, C; Slegers, G; Thonissen, T; Van De Wiele, C | 1 |
| De Porre, PM; DeVore, RF; Heymach, JV; Jia, X; Johnson, BE; Johnson, DH; Khuri, FR; Richards, HM; Safran, H; Schlabach, LL; Yunus, F; Zhang, S | 1 |
| Abbruzzese, A; Budillon, A; Caraglia, M; Colao, A; D'Alessandro, AM; Giuberti, G; Marra, M; Prete, SD; Tagliaferri, P; Tassone, P; Venuta, S; Viscomi, C; Vitale, G | 1 |
| Flournoy, N; Paul, RK; Rosenberger, WF | 1 |
| Atkins, D; Belly, RT; Karp, JE; Lancet, JE; Raponi, M; Wang, Y | 1 |
| Kinsella, BT; O'Meara, SJ | 1 |
| Claiborne, A; Cohen, J; Frost, D; Gu, W; Hasvold, L; Hutchins, C; Jakob, CG; Li, Q; Li, T; Muchmore, S; Rosenberg, SH; Sham, HL; Stoll, VS | 1 |
| Claiborne, A; Cohen, J; Frost, D; Gu, W; Gwaltney, SL; Hutchins, C; Li, Q; Li, T; Rosenberg, SH; Sham, HL; Stoll, VS; Wang, GT; Wang, X; Woods, KW | 1 |
| Andre, T; Belly, R; Cunningham, D; de Gramont, A; Dostalova, J; Humblet, Y; Illes, A; Iveson, T; Kourteva, G; Palmer, PA; Park, YC; Perez-Ruixo, JJ; Rao, S; Scheithauer, W; Smakal, M | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H | 2 |
| Korycka, A; Robak, T; Smolewski, P | 1 |
| Berk, S; Gajewski, TF; Harlin, H; Karrison, T; Larson, RA; Odenike, OM; Ratain, MJ; Sprague, E; Stock, W; Zimmerman, TM | 1 |
| Iida, S | 1 |
| Cassinat, B; Chomienne, C; Gervais, N; Larghero, J; Padua, RA; Rain, JD; Rousselot, P; Schlageter, MH | 1 |
| Evans, L | 1 |
| Boerman, O; Burvenich, I; Cornelissen, B; Kersemans, V; Oltenfreiter, R; Slegers, G; Vanderheyden, JL; Vandewiele, C | 1 |
| Balis, FM; Chow, C; Clark, G; Eng-Wong, J; Gantz, SB; Jayaprakash, N; Lebowitz, PF; Venzon, D; Widemann, BC; Zujewski, J | 1 |
| Doroshow, JH; Frankel, P; Gandara, DR; Gumerlock, PH; Kawaguchi, T; Lara, PN; Lau, DH; Law, LY; Lenz, HJ; Twardowski, P; Wright, JJ | 1 |
| Alsina, M; Beam, C; Beaupre, DM; Dalton, W; Gerbino, E; Hamilton, AD; Kerr, WG; Lichtenheld, MG; Mackley, PA; Muro-Cacho, C; Sebti, SM; Zhu, K | 1 |
| Helbig, G; Hołowiecki, J | 1 |
| Choudary, A; Freeman, JW; Venkatasubbarao, K | 1 |
| Mardiak, J; Moore, M; Palmer, PA; Perez-Ruixo, JJ; Rosenberg, JE; Sahasrabudhe, D; Seigne, JD; Small, EJ; Vaughn, DJ; von der Maase, H | 1 |
| Bonanno, E; Capriotti, G; Cornelissen, B; Dierckx, RA; Kersemans, V; Lahorte, C; Signore, A; Slegers, G; Van de Wiele, C | 1 |
| Elhamri, M; Thomas, X | 1 |
| Zhang, GS | 1 |
| Abbruzzese, A; Budillon, A; Caponigro, F; Caraglia, M; Marra, M; Tagliaferri, P | 1 |
| Feldman, EJ | 2 |
| Kano, Y; Komatsu, N; Miyoshi, T; Muroi, K; Nagai, T; Nakamura, M; Ohmine, K; Ozawa, K | 1 |
| Cohen, J; Frost, D; Galicia, T; Gu, WZ; Hutchins, C; Li, Q; Li, T; Rosenberg, SH; Sham, HL; Stoll, VS; Woods, KW | 1 |
| Abbruzzese, A; Budillon, A; Caponigro, F; Caraglia, M; Di Gennaro, E; Facchini, G; Giuberti, G; Iaffaioli, R; Marra, M | 1 |
| Creutzig, U; Gibson, BE; Goemans, BF; Hählen, K; Harlow, A; Heinrich, MC; Kaspers, GJ; Loonen, AH; Reinhardt, D; Zwaan, CM | 1 |
| Buckner, FS; Gelb, MH; Hucke, O; Verlinde, CL | 1 |
| Adjei, AA | 1 |
| Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R | 1 |
| Abbruzzese, JL; Giguere, JK; Iqbal, S; Macdonald, JS; McCoy, S; Wade, JL; Whitehead, RP | 1 |
| Kurzrock, R | 1 |
| Abrey, L; Chang, S; Cloughesy, TF; DeAngelis, L; Fink, K; Groves, M; Junck, L; Kuhn, J; Lamborn, K; Lieberman, FS; Mehta, M; Paquette, S; Prados, M; Robins, HI; Schiff, D; Sebti, SM; Wen, P; Wright, J; Yung, A | 1 |
| Appels, NM; Beijnen, JH; Schellens, JH | 1 |
| Bendale, P; Gelb, MH; Huyer, G; Mallampalli, MP; Michaelis, S | 1 |
| Odenike, O; Tefferi, A | 1 |
| Ashihara, E; Fuchida, S; Inaba, T; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R; Yamada, N | 1 |
| Beijnen, JH; Crul, M; Howes, A; Pluim, D; Schellens, JH; Siegel-Lakhai, WS; Solanki, B; Sparidans, RW; Zhang, S | 1 |
| Grever, MR | 1 |
| Fourie, A; Gu, Y; Huang, JF; Karlsson, L; Lai, KT; Xue, X | 1 |
| Sekeres, MA | 1 |
| End, DW; Grubbs, CJ; Lemon, WJ; Lu, Y; Lubet, RA; Wang, Y; Yao, R; You, M | 1 |
| Arceci, RJ; Balis, FM; Blaney, SM; End, D; Fox, E; Gillespie, A; Jayaprakash, N; Palumbo, JS; Pitney, A; Salzer, WL; Whitcomb, P; Widemann, BC; Zannikos, P | 1 |
| Beaupre, DM; Boulware, D; Buzzeo, RW; Colaco, NM; Dalton, WS; Parquet, NA; Perez, LE; Wright, G; Yanamandra, N | 1 |
| Dalenc, F; Favre, G; Faye, JC; Giamarchi, C; Petit, M; Poirot, M | 1 |
| Mesa, RA | 1 |
| Franc, MA; Francke, S; Ozdemir, V; Perez-Ruixo, JJ; Piotrovsky, V; Zannikos, P | 1 |
| Anderson, E; Bundred, NJ; Clarke, RB; Knox, F; Morris, J; Wärnberg, F; White, D | 1 |
| Jiang, D; Zhang, M | 1 |
| Christov, K; End, DW; Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE; Yao, R; You, M | 1 |
| Abbruzzese, JL; Dakhil, SR; Lenz, HJ; Macdonald, JS; McCoy, S; Neubauer, MA; Rivkin, SE; Tanaka, MS; Whitehead, RP | 1 |
| Borner, MM | 1 |
| Alyaqoub, FS; Gunning, WT; Kramer, PM; Lubet, RA; Pereira, MA; Steele, VE; Tao, L | 2 |
| Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
| Hershman, D; Hopkins, U; Hoschander, S; Kazi, A; Lee, D; Li, T; Malafa, M; Moulder, S; Munster, P; Pellegrino, C; Sebti, SM; Sparano, JA; Vahdat, L; Wright, JJ | 1 |
| Cacalano, NA; Iwamoto, KS; Liao, YP; McBride, WH; Mischel, PS; Wang, CC | 1 |
| De Porre, P; Hayes, S; Perez-Ruixo, JJ; Piotrovskij, V; Zannikos, P; Zhang, S | 1 |
| Bergh, C; Billig, H; Friberg, PA; Rung, E | 1 |
| Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; DeAngelis, LM; Fink, KL; Gilbert, MR; Groves, MD; Junck, L; Kuhn, J; Lamborn, KR; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Schiff, D; Wen, PY; Wright, J; Yung, WK | 1 |
| Cohen, RB; Eckhardt, SG; Gore, L; Gustafson, D; Holden, SN; Mikule, C; Morrow, M; O'Bryant, CL; Palmer, PA; Persky, M; Pierson, AS; Zhang, S | 1 |
| Awada, A; De Porre, P; Dirix, LY; Francois, M; Fumoleau, P; Piccart-Gebhart, M; Verhaeghe, T; Zannikos, P; Zhang, S | 1 |
| Beijnen, JH; Boot, H; Chang, I; Crul, M; De Porre, P; Schellens, JH; Siegel-Lakhai, WS; Zhang, S | 1 |
| Adjei, AA; Bruzek, LM; Feldman, EJ; Garrett-Mayer, E; Gojo, I; Gotlib, J; Greenberg, PL; Greer, J; Karp, JE; Kaufmann, SH; Lancet, JE; Liesveld, JL; Morris, L; Park, Y; Wright, JJ | 1 |
| Abbruzzese, A; Baldi, A; Bertieri, R; Budillon, A; Caraglia, M; D'Alessandro, AM; Leonetti, C; Marra, M; Meo, G; Santini, D; Tonini, G; Zupi, G | 1 |
| Aul, C; Cripe, L; De Porre, P; Fenaux, P; Germing, U; Kantarjian, H; Kerstens, R; Kurzrock, R; Mufti, GJ; Raza, A | 1 |
| Eckhardt, SG; Landau, HJ; Lockerbie, RO; Medeiros, BC; Morrow, M; Pitts, T | 1 |
| Harousseau, JL | 1 |
| Hayashi, Y | 1 |
| Angibaud, P; Bourdrez, X; End, DW; Lezouret, P; Merillon, S; Mevellec, L; Meyer, C; Pilatte, I; Poncelet, V; Roux, B; Van Dun, J; Venet, M; Wouters, W | 1 |
| De Porre, P; Fenaux, P; Harousseau, JL; Huguet, F; Lancet, JE; Lowenberg, B; Rackoff, W; Reiffers, J; Stone, R; Thomas, X; Zhang, S | 1 |
| Chen, W; Chow, A; Hayes, S; Perez-Ruixo, JJ; Zhang, S | 1 |
| Atkins, D; Harousseau, JL; Lancet, JE; Löwenberg, B; Rackoff, W; Raponi, M; Stone, R; Wang, Y; Zhang, Y | 1 |
| Armand, JP; Burnett, AK; Drach, J; Harousseau, JL; Löwenberg, B; San Miguel, J | 1 |
| Khuri, FR; Liu, X; Lonial, S; Qiu, Y; Sun, SY; Yue, P; Zou, W | 1 |
| Awada, A; De Porre, P; de Valeriola, D; Gil, T; Lalami, Y; Piccart-Gebhart, MJ; Zhang, S | 1 |
| Berk, S; Gajewski, TF; Ho, AW; Kuna, T; Marks, RE; Robbel, C | 1 |
| Bouffet, E; Drake, JM; Parkin, P; Rutka, JT; Serletis, D; Shroff, M | 1 |
| Alaux, B; Berchery, D; Bousquet, P; Catalaa, I; Dalenc, F; De Porre, P; Delannes, M; Laprie, A; Moyal, EC; Poublanc, M; Sabatier, J; Toulas, C | 1 |
| Camoriano, JK; Erlichman, C; Finke, C; Geyer, SM; Kaufmann, SH; Lasho, T; Li, CY; Mesa, RA; Pardanani, A; Rivera, CE; Tefferi, A; Wright, J; Wu, W | 1 |
| Barbarat, A; Camara-Clayette, V; Coiffier, B; Ribrag, V; Rolland, D; Salles, G; Thieblemont, C | 1 |
| Hanafusa, T; Kikuchi, S; Komatsu, N; Miyoshi, T; Nagai, T; Nakamura, M; Ohmine, K; Ozawa, K | 1 |
| Abbruzzese, A; Arra, C; Baldi, A; Barbieri, A; Budillon, A; Caraglia, M; D'Alessandro, AM; Marra, M; Meo, G; Rapp, UR; Tagliaferri, P; Tassone, P; Venuta, S; Viscomi, C | 1 |
| Cortes, J; Ebarb, T; Faderl, S; Garcia-Manero, G; Giles, F; Jones, D; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Thomas, D | 1 |
| Bessems, A; De Porre, PM; Dodwell, DJ; Howes, AJ; Johnston, SR; Manikhas, GM; Neven, P; Park, YC; Perez Ruixo, JJ; Romieu, G; Semiglazov, VF; Spaeth, D; Wardley, AM | 1 |
| Detre, S; Dowsett, M; Head, JE; Howes, A; Johnston, SR; Kaye, S; Martin, LA; Pancholi, S; Quinn, E; Salter, J | 1 |
| Cohen, K; Fouladi, M; Helton, KJ; Holmes, E; Laningham, F; Nicholson, HS; Pollack, IF; Speights, RA; Wright, J; Zhou, T | 1 |
| De Porre, P; Dossey, L; Fan, H; Feldman, EJ; Gojo, I; Gotlib, J; Greenberg, PL; Harousseau, JL; Karp, JE; Lancet, JE; Lee, G; Löwenberg, B; Morris, LE; Raponi, M; Stone, RM; Wang, Y; Wright, JJ | 1 |
| Burnett, AK; Kell, J | 1 |
| Beran, M; Blascovich, MA; Bucher, C; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; Kurzrock, R; Pilat, SR; Sebti, SM; Verstovsek, S; Wright, JJ | 1 |
| Banerjee, A; Blaney, SM; Boyett, JM; Broniscer, A; Fouladi, M; Geyer, JR; Haas-Kogan, DA; Kocak, M; Kun, LE; McKnight, T; Poussaint, TY; Prados, MD | 1 |
| Chintala, L; El Naggar, AK; Gagel, R; Hong, D; Kurzrock, R; Wright, J; Ye, L | 1 |
| Garrett-Mayer, E; Gojo, I; Gore, SD; Greer, J; Karp, JE; Klein, M; Lancet, JE; Levis, MJ; Morris, L; Smith, BD; Wright, JJ | 1 |
| Iacobucci, I; Martinelli, G; Ottaviani, E; Paolini, S | 1 |
| Cohen, PR; Diwan, AH; Evans, HL; Hong, DS; Kurzrock, R; Prieto, VG; Reddy, SB; Tannir, NM; Wright, JJ | 1 |
| Almenara, JA; Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Venditti, CA | 1 |
| Bouche, O; Bugat, R; De Porre, P; Eckhardt, SG; Maurel, J; Michiels, B; Smith, D; Steward, WP; van de Velde, H | 1 |
| Desideri, S; Fisher, J; Grossman, S; Lesser, G; Lustig, R; Mikkelsen, T; Wright, J; Ye, X | 1 |
| Bai, F; Blaskovich, MA; Chen, X; Djeu, JY; Edwards, TD; Epling-Burnette, PK; Loughran, TP; Moscinski, L; Painter, JS; Sebti, S; Sokol, L; Wei, S; Yoder, JA; Zhou, J; Zou, J | 1 |
| Anastasiades, A; Bazdiara, I; Bourikas, G; De Coster, R; De Porre, P; Kotsianidis, I; Margaritis, D; Pantelidou, D; Spanoudakis, E; Tsatalas, C | 1 |
| Avallone, H; Cao, K; Capell, BC; Chen, X; Collins, FS; Conneely, KN; Erdos, MR; Faddah, DA; Ganesh, SK; Kolodgie, FD; Nabel, EG; Olive, M; Qu, X; San, H; Tavarez, UL; Virmani, R | 1 |
| Brandwein, JM; Gupta, V; Howson-Jan, K; Leber, BF; MacAlpine, K; Minden, MD; Moore, M; Schimmer, AD; Schuh, AC; Wright, J; Yee, KW | 1 |
| Adjei, AA; Dai, NT; Feldman, EJ; Flatten, K; Garrett-Mayer, E; Gore, SD; Greer, JM; Ironside, V; Karp, JE; Kaufmann, SH; Le, SB; Levis, MJ; Loegering, DA; Meng, XW; Morris, LE; Ricklis, RM; Ritchie, E; Roboz, G; Schneider, PA; Smith, BD; Talbott, T; Wright, JJ | 1 |
| Christos, PJ; Hershman, DL; Hoschander, S; Li, T; O'Brien, K; Sparano, JA; Vahdat, LT; Wright, JJ | 1 |
| Gore, SD | 1 |
| Karp, J | 1 |
| Aoki, Y; Asoh, K; Ebiike, H; Fukami, TA; Hyoudoh, I; Ishii, N; Kawasaki, K; Kohchi, M; Kondoh, O; Masubuchi, M; Ohtsuka, T; Sakaitani, M; Shimma, N; Shiratori, Y; Tsukaguchi, T | 1 |
| Buckner, FS; Gelb, MH; Karimi, M; Kraus, JM; Lepesheva, GI; Verlinde, CL | 1 |
| Blum, S; Gattermann, N; Germing, U; Haas, R; Habersang, K; Kuendgen, A; Möller, I | 1 |
| Coppola, D; Fineberg, S; Hershman, D; Hopkins, U; Hoschander, S; Kazi, A; Kleer, C; Lee, D; Li, T; Malafa, M; Merajver, S; Moulder, S; Munster, P; Negassa, A; Pellegrino, C; Sebti, SM; Sparano, JA; Vahdat, L; Wright, JJ | 1 |
| de Jonge-Peeters, SD; de Vries, EG; Kuipers, F; van der Weide, K; Vellenga, E | 1 |
| Barosi, G; Rosti, V | 1 |
| Alexeeva, JA; Bessems, A; Beutel, G; Bordessoule, D; Brandwein, JM; Burnett, AK; De Porre, P; Dombret, H; Golenkov, AK; Harousseau, JL; Howes, AJ; Jedrzejczak, WW; Khuageva, NK; Maertens, J; Martinelli, G; Masszi, T; Mollgard, L; Ossenkoppele, GJ; Park, YC; Robak, T; Thomas, X; Tothova, E; Vidriales, MB | 1 |
| Abbruzzese, A; Caraglia, M; D'Alessandro, A; Giuberti, G; Iannuzzi, C; Irace, G; Misso, G; Sirangelo, I; Vilasi, S | 1 |
| Arif, J; Buckner, FS; Chennamaneni, NK; Gelb, MH | 1 |
| Blaskovich, MA; El Naggar, AK; Gagel, RF; Hong, DS; Khan, R; Kurzrock, R; Moulder, S; Naing, A; Newman, RA; Ng, CS; Sebti, SM; Sherman, SI; Tannir, NM; Trent, J; Wheler, JJ; Wright, JJ; Ye, L | 1 |
| Bouabdallah, R; Briere, J; Chassagne-Clement, C; De Kerviler, E; Franchi, P; Ghesquieres, H; Haioun, C; Houlgatte, R; Jais, JP; Jardin, F; Raponi, M; Ribrag, V; Rolland, D; Thieblemont, C | 1 |
| Le Moulec, S; Loriot, Y; Soria, JC | 1 |
| Fujiwara, S; Nagai, T; Ohmine, K; Ozawa, K; Sakurai, C; Uesawa, M | 1 |
| Allal, BC; Chaoui, K; Dalenc, F; Doisneau-Sixou, SF; Favre, G; Filleron, T; Lauwers-Cances, V; Malissein, E; Marsili, S; Meunier, E; Monsarrat, B; Renée, N; Roché, H; Schiltz, O | 1 |
| Steensma, DP | 1 |
| Epling-Burnette, PK; Loughran, TP | 1 |
| Geryk-Hall, M; Hughes, DP; Yang, Y | 1 |
| Astolfi, A; Biagi, C; Chiarini, F; Franzoni, M; Masetti, R; Melchionda, F; Pession, A; Serravalle, S | 1 |
| Arif, J; Buckner, FS; Chennamaneni, NK; Gelb, MH; Karimi, M; Kraus, JM; McGuffin, SA; Tatipaka, HB; Verlinde, CL | 1 |
| Li, M; Liu, A; Liu, B; Luo, X; Yu, H; Zheng, H | 1 |
| Boise, LH; Chen, J; David, E; Flowers, CR; Kaufman, JL; Lonial, S; Marcus, AI; Schafer-Hales, K; Sun, SY; Torre, C | 1 |
| Adamson, PC; Arceci, RJ; Balis, FM; Blaney, SM; Fox, E; Goodspeed, W; Goodwin, A; Jayaprakash, N; Widemann, BC; Wright, JJ; Zannikos, P | 1 |
| Abrey, L; Chang, SM; Cloughesy, TF; DeAngelis, LM; Demopoulos, A; Drappatz, J; Fine, HA; Fink, K; Kesari, S; Lamborn, KR; Lassman, AB; Lieberman, FS; Malkin, MG; Mehta, MP; Nghiemphu, PL; Prados, MD; Robins, HI; Torres-Trejo, A; Wen, PY | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Thomas, DA; Verstovsek, S; Wright, JJ | 1 |
| Boyett, JM; Geyer, R; Haas-Kogan, D; Kieran, MW; Kun, L; Ng, S; Pollack, IF; Poussaint, TY; Prabhu, SP; Vajapeyam, S | 1 |
| Chandhasin, C; Kurzrock, R; Tsimberidou, AM | 1 |
| Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S | 1 |
| Bidyasar, S; Busaidy, NL; Cabanillas, ME; El Naggar, AK; Hernandez, M; Hong, DS; Kurzrock, R; Naing, A; Sherman, SI; Tsimberidou, AM; Waguespack, SG; Wheler, J; Wright, J; Ye, L | 1 |
| Boyett, JM; Cha, S; Geyer, R; Haas-Kogan, D; Kocak, M; Kun, LE; Packer, RI; Patay, Z; Pollack, IF; Poussaint, TY; Robertson, RL; Vajapeyam, S; Vezina, G; Zimmerman, R | 1 |
| Banerjee, A; Boyett, JM; Broniscer, A; Fouladi, M; Geyer, JR; Haas-Kogan, DA; Kocak, M; Kun, LE; Minturn, JE; Packer, RJ; Pollack, IF; Poussaint, TY; Prados, MD | 1 |
| Beaupre, DM; Buzzeo, RW; Cuevas, J; Gabriel, M; Hazlehurst, LA; Mari, Y; Yanamandra, N | 1 |
| Baer, MR; Gojo, I | 1 |
| Crovella, S; De Leo, L; Decorti, G; Marcuzzi, A; Pontillo, A; Tommasini, A | 1 |
| Forman, SJ; Frankel, P; Karanes, C; Kirschbaum, MH; Newman, EM; O'Donnell, MR; Popplewell, L; Pulone, B; Rincon, A; Stein, AS; Synold, T; Tuscano, J; Wright, J; Zain, JM | 1 |
| Allmer, C; Ansell, SM; Colgan, JP; Ding, H; Gupta, M; Habermann, TM; Hohl, R; Inwards, DJ; Johnston, PB; Kaufmann, SH; Kurtin, PJ; Link, BK; Loegering, D; Markovic, SN; Maurer, MJ; Micallef, IN; Nowakowski, GS; Peterson, K; Porrata, LF; Schneider, P; Tang, H; Thompson, CA; Weiner, G; Witzig, TE | 1 |
| Burnett, AK; Hills, RK | 1 |
| Bai, F; Blaskovich, MA; Connolly, K; Djeu, JY; Epling-Burnette, P; Loughran, TP; Painter, JS; Sebti, S; Sokol, L; Sotomayor, E; Villagra, AV; Wei, S; Zou, J | 1 |
| Carraway, HE; Derecho, C; Feldman, EJ; Galkin, S; Garret-Mayer, E; Gocke, CD; Gore, SD; Greer, JM; Ironside, V; Karp, JE; Kaufmann, SH; Levis, MJ; Malek, S; McDevitt, MA; Morris, LE; Palma, J; Raponi, M; Ritchie, EK; Roboz, GR; Smith, BD; Vener, TI; Wang, Y; Wright, JJ | 1 |
| Bentke, A; Krzykowska-Petitjean, K; Laidler, P; Małecki, J; Ostrowska, B | 2 |
| Akerley, WL; Flaherty, LE; Kirkwood, JM; Lao, CD; Margolin, KA; Moon, J; Othus, M; Sondak, VK; Sosman, JA | 1 |
| Christos, PJ; Feldman, EJ; Gergis, U; Mayer, S; Ritchie, EK; Roboz, GJ; Scandura, JM; Wissa, U | 1 |
| Gradishar, WJ; Guo, M; Li, T; Perez, EA; Sledge, GW; Sparano, JA; Wang, M | 1 |
| Abbruzzese, A; Caraglia, M; Giordano, A; Giuberti, G; Grimaldi, A; Lombardi, A; Misso, G; Ricciardiello, F; Tagliaferri, P | 1 |
| Burnett, AK; Cavanagh, J; Culligan, D; Hills, RK; Kell, J; Milligan, D; Russell, NH; Virchis, A; Wheatley, K | 1 |
| Bahia, MT; Buckner, FS; Charman, SA; Chatelain, E; Chennamaneni, NK; Gelb, MH; Hulverson, MA; Laydbak, JU; Lepesheva, GI; Scandale, I; Shackleford, DM; Suryadevara, PK; Verlinde, CL; White, KL | 1 |
| Dürr, C; Finke, J; Fisch, P; Gerlach, U; Hechinger, AK; Hofmann, M; Leonhardt, F; Maas, K; Marks, R; Pircher, H; Prinz, G; Zeiser, R | 1 |
| Asadpour-Zeynali, K; Doerksen, RJ; Ghasemi, S; Jouyban, A; Shayanfar, A; Soltani, S | 1 |
| Jawad, M; Pallis, M; Russell, NH; Seedhouse, C; Tandon, K; Yu, N | 1 |
| Busceti, MT; Caraglia, M; Falcone, D; Fratto, D; Gallelli, L; Maselli, R; Pelaia, G; Renda, T; Savino, R; Terracciano, R; Vatrella, A | 1 |
| Blaskovich, MA; Bucher, C; Gajewski, TF; Haluska, F; Johnson, J; Linette, G; Niedzwiecki, D; Salama, AK; Sebti, SM | 1 |
| Benouaich-Amiel, A; Cohen-Jonathan Moyal, E; De Porre, P; Delisle, MB; Ducassou, A; Favre, G; Filleron, T; Ken, S; Laprie, A; Lubrano, V; Poublanc, M; Sol, JC; Toulas, C; Uro-Coste, E; Verrelle, P | 1 |
| Benchitrit, J; Drüeke, TB; Edelman, A; Galmiche, A; Guerrera, IC; Guillonneau, F; Ivanovski, O; Joki, N; Lacour, B; Lucas, A; Maizel, J; Marçon, F; Massy, ZA; Nguyen-Khoa, T; Nikolov, IG; Phan, O | 1 |
| Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J | 1 |
| Adjei, AA; Ding, H; Flatten, KS; Huang, S; Karp, JE; Kaufmann, SH; Loegering, DA; McDonald, JS; Meng, XW; Oberg, AL; Peterson, KL; Riska, SM; Schneider, PA; Sinicrope, FA; Yun, S | 1 |
| Fernandes, PA; Moorthy, NS; Ramos, MJ; Sousa, SF | 1 |
| Alvarez, RH; Andreopoulou, E; Cristofanilli, M; Fehn, K; Fineberg, S; Han, HS; Hershman, DL; Pellegrino, CM; Raptis, G; Sparano, JA; Vahdat, LT; Valero, V; Vigoda, IS; Wright, JJ | 1 |
| Crovella, S; Kleiner, G; Marcuzzi, A; Monasta, L; Piscianz, E; Tricarico, PM; Zanin, V | 1 |
| Fang, H; Gao, P; Jiang, X; Qiao, J | 1 |
| Beese, LS; Hast, MA; Hellinga, HW; Lubock, NB; Mabanglo, MF | 1 |
| Appelbaum, FR; Erba, HP; Gundacker, HM; Kirschbaum, MH; Kopecky, KJ; Larson, RA; Othus, M; Slovak, ML; Tallman, MS; Walter, RB | 1 |
| Balis, FM; Belasco, J; Dombi, E; Fox, E; Gillespie, A; Goldman, S; Kieran, MW; Kim, A; Korf, BR; Martin, S; Patronas, N; Perentesis, JP; Reddy, A; Salzer, W; Solomon, J; Steinberg, SM; Widemann, BC; Wolters, PL; Wright, JJ | 1 |
| Conney, AH; Cui, XX; Ding, N; Du, Z; Gao, Z; Hu, C; Huang, H; Lin, Y; Rabson, AB; Shih, WJ; Wei, X; Zheng, X | 1 |
| Prados, MD | 1 |
| Hirai, S; Hisaka, S; Ichinose, F; Kaneki, M; Shirozu, K; Tanaka, T | 1 |
| Berry, I; Catalaa, I; Celsis, P; Cohen-Jonathan Moyal, E; Deviers, A; Filleron, T; Ken, S; Laprie, A; Laruelo, A; Lubrano, V; Mogicato, G; Rowland, B | 1 |
| Ahmed, TA; Hayslip, J; Leggas, M | 1 |
| Erba, HP | 1 |
| Alonzo, TA; Arceci, RJ; Balis, FM; Bunin, NJ; Castleberry, RP; Cheng, JW; Cooper, TM; Emanuel, PD; Gerbing, RB; Jayaprakash, N; Liu, YL; Loh, ML; Stieglitz, E; Ward, AF; Widemann, BC | 1 |
| Berry, I; Catalaa, I; Celsis, P; Deviers, A; Filleron, T; Ken, S; Khalifa, J; Laprie, A; Lotterie, JA; Lubrano, V; Moyal, EC; Péran, P | 1 |
| Ha, YR; Hong, Y; Hwang, BG; Lee, SJ; Yang, HW | 1 |
| Godbole, S; Paranjape, R; Pawar, J; Shete, A; Suryawanshi, P; Thakar, M | 1 |
| Hanai, J; Ikegami, Y; Kaneki, M; Kuriyama, N; Nakazawa, H; Oki, M; Sukhatme, VP; Tanaka, T | 1 |
| Ishikawa, O; Motegi, S; Ogino, S; Perera, B; Takeuchi, Y; Uchiyama, A; Yamada, K; Yokoyama, Y | 1 |
| Abdul-Salam, VB; Ahmetaj-Shala, B; Aldabbous, L; Dubois, OD; Duluc, L; Iannone, L; Mahomed, AS; Mitchell, J; Oliver, E; Storck, EM; Tate, EW; Wilkins, MR; Wojciak-Stothard, B; Zhao, L | 1 |
| Merkus, D; Schermuly, RT | 1 |
| Abrey, LE; Aldape, K; Chang, S; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Ebiana, VA; Gilbert, M; Kuhn, J; Levin, VA; Lieberman, F; Mehta, MP; Nghiemphu, PL; Prados, M; Robins, HI; Wen, P; Wright, JJ; Yung, WKA | 1 |
| Arun, B; Buzdar, AU; Hortobagyi, GN; Moulder, SL; Murray, JL; Murthy, RK; Shroff, GS; Stalzer, CJ; Szklaruk, J; Valero, V; Yam, C; Yang, W | 1 |
| Adjei, A; Allred, J; Goetz, M; Jazieh, K; Kaufmann, SH; Lim, VS; Molina, J; Reid, J; Yin, J | 1 |
| Cavaco, BM; Leite, V; Lopes-Ventura, S; Marques, IJ; Matias, AT; Moura, MM; Pojo, M | 1 |
| Babic, T; Buric, SS; Dinic, J; Hadzic, S; Pesic, M; Radojkovic, D; Rankov, AD | 1 |
| Aboelfotoh Hendy, A; Chen, X; Chen, XL; Xing, J | 1 |
| Jones, RD; Li, H; Liao, J; Sun, L; Tong, X; Xu, D; Yang, GY | 1 |
| Eşkazan, AE; Özgür Yurttaş, N | 1 |
| Akahoshi, T; Guo, J; Mizuta, Y; Murata, M; Shirozu, K; Yamaura, K | 1 |
| Alonso-Alonso, R; Burrows, F; Esteve-Codina, A; Fuste, B; García-Diaz, N; Gualberto, A; Gut, M; Martínez, N; Merino, D; Mondéjar, R; Pérez, C; Piris, MÁ; Rodríguez, M; Scholz, C; Vaqué, JP | 1 |
| Chung, W; Hong, JH; Jeong, BC; Jeong, DE; Jo, A; Joo, KM; Lee, HO; Lee, HW; Lim, JE; Nam, DH; Park, SH; Park, WY | 1 |
| Aggarwal, R; Brose, M; Chau, NG; Cohen, EEW; Gualberto, A; Guenette, JP; Hanna, GJ; Ho, AL; Metcalf, R; Pérez-Ruiz, E; Razaq, M; Sayehli, CM; Scholz, C; Wilhelm, C; Wong, DJ | 1 |
| Choi, HY; Gualberto, A; Jeong, BC; Kwon, GY; Lee, HW; Park, SH; Sa, JK; Scholz, C; Sung, HH | 1 |
| Burrows, F; Calleja-Valera, JL; Chillà, A; Ferrara, N; Gilardi, M; Goto, Y; Gualberto, A; Gutkind, JS; Janes, MR; Mikulski, Z; Molinolo, AA; Proietto, M; Vanoni, M; Wang, Z | 1 |
| Kwon, M; Lee, DW; Lee, HN; Lee, W | 1 |
| Chen, J; Goodin, S; Li, DL; Ma, YR; Ma, YY; Ren, X; Wang, X; Xu, XT; Zhang, K; Zhao, DG; Zheng, X; Zhou, RP | 1 |
| Egawa, N; Ito, K; Kitagawa, H; Kitajima, Y; Matsufuji, S; Noshiro, H; Okuyama, K; Tanaka, T; Yamada, K | 1 |
| Fernandez-Juarez, G; Gimenez-Moyano, S; Guerrero-Marquez, C; Martinez de la Cruz, P; Mielgo-Rubio, X; Shabaka, A | 1 |
| Blijlevens, N; de Witte, T; Langemeijer, S; Muus, P; van Bijnen, S | 1 |
| Chen, Z; Chen, ZG; El-Deiry, M; Griffith, CC; Nannapaneni, S; Patel, M; Saba, NF; Shin, DM; Shu, L; Sun, Y; Wang, D; Wang, X | 1 |
| Appelbaum, FR; Cooper, BW; Craig, MD; Kaminer, LS; Karp, J; Ketterling, RP; Larson, RA; Lazarus, H; Litzow, MR; Luger, SM; Makary, AZ; Paietta, E; Rowe, JM; Rybka, WB; Tallman, MS; Wang, VX | 1 |
| Chen, L; Liu, X; Schell, T; Spiegelman, VS; Sundstrom, JM; Wang, HG; Wills, CA; Young, MM; Zhang, J; Zhao, Y; Zhou, M | 1 |
52 review(s) available for tipifarnib and carbostyril
| Article | Year |
|---|---|
Cancer therapy. New strategies and treatment modalities for optimizing patient outcomes.
Topics: Alkyl and Aryl Transferases; Anemia; Enzyme Inhibitors; Erythropoietin; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Recombinant Proteins | 2001 |
Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
Topics: Alkyl and Aryl Transferases; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Quinolones; Signal Transduction | 2001 |
Current status of clinical trials of farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Leukemia; Neoplasms; Piperidines; Pyridines; Quinolones; Signal Transduction | 2001 |
Farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins | 2001 |
Farnesylated proteins and cell cycle progression.
Topics: Alkyl and Aryl Transferases; Animals; Cell Cycle; Chromosomal Proteins, Non-Histone; Enzyme Inhibitors; Farnesyltranstransferase; G1 Phase; Humans; Microfilament Proteins; Monomeric GTP-Binding Proteins; Neuropeptides; Protein Prenylation; Quinolones; Ras Homolog Enriched in Brain Protein; Resting Phase, Cell Cycle; Tumor Cells, Cultured | 2001 |
Tipifarnib (Janssen Pharmaceutica).
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Ataxia; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drugs, Investigational; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Structure-Activity Relationship; Thrombocytopenia; Treatment Outcome | 2002 |
Farnesyl transferase inhibitors as anticancer agents.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Cell Division; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Imidazoles; Neoplasms; Piperidines; Pyridines; Quinolones; Tumor Cells, Cultured | 2002 |
[New therapeutic targets and strategies in lung cancer].
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Metalloendopeptidases; Multicenter Studies as Topic; Piperazines; Polyisoprenyl Phosphates; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolones; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Agents targeting ras signaling pathway.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzamides; Benzodiazepines; Enzyme Inhibitors; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Imidazoles; MAP Kinase Kinase Kinases; Oligonucleotides, Antisense; Phosphorothioate Oligonucleotides; Piperidines; Proto-Oncogene Proteins c-raf; Pyridines; Quinolones; Signal Transduction | 2002 |
Farnesyltransferase inhibitors in breast cancer therapy.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fluorouracil; Humans; Mice; Neoplasm Proteins; Paclitaxel; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
[Innovative treatment in oncology].
Topics: Antibodies, Monoclonal; Humans; Neoplasms; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinolones | 2002 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Preclinical and clinical evaluation of farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Imidazoles; Piperidines; Pyridines; Quinolones | 2003 |
Farnesyl transferase inhibitors in the treatment of breast cancer.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins | 2003 |
Inhibiting Ras signaling in the therapy of breast cancer.
Topics: Alkyl and Aryl Transferases; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Female; GTP-Binding Proteins; Humans; Mutation; Neoplasm Metastasis; Quinolones; ras Proteins; Signal Transduction | 2003 |
Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Mice; Molecular Structure; Neoplasms; Protein Prenylation; Quinolones; Structure-Activity Relationship | 2003 |
Farnesyl transferase inhibitors in myeloid malignancies.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myeloid, Acute; Models, Biological; Myeloproliferative Disorders; Piperazines; Pyrimidines; Quinolones; ras Proteins; Signal Transduction | 2003 |
Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Enzyme Inhibitors; Gastrointestinal Neoplasms; Gemcitabine; Humans; Paclitaxel; Quinolones; Radiotherapy, Conformal; Treatment Outcome | 2003 |
Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Piperidines; Protein Prenylation; Proto-Oncogene Mas; Pyridines; Quinolones; ras Proteins; Signal Transduction | 2003 |
Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Quinolones | 2003 |
[Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor].
Topics: Animals; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyridines; Pyrimidines; Quinolones; Randomized Controlled Trials as Topic; Thionucleotides | 2004 |
Farnesyl transferase inhibitors for patients with lung cancer.
Topics: Alkyl and Aryl Transferases; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Farnesyltranstransferase; Humans; Imidazoles; Lung Neoplasms; Quinolones; Signal Transduction; Treatment Outcome | 2004 |
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins; Signal Transduction | 2004 |
[Multiple myeloma: from molecular pathogenensis to the development of molecular targeting therapies].
Topics: Antineoplastic Agents; Chromosomal Instability; Chromosome Deletion; Enzyme Inhibitors; Humans; Multiple Myeloma; Quinolones; Signal Transduction | 2004 |
[Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Farnesyltranstransferase; Genes, ras; GTP-Binding Proteins; Guanosine Triphosphate; Humans; Imidazoles; Neoplasms; Piperidines; Point Mutation; Pyridines; Quinolones; Signal Transduction | 2004 |
[Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
Topics: Alkyl and Aryl Transferases; Benzodiazepines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 1; Myeloproliferative Disorders; Piperidines; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Quinolones; ras Proteins; rho GTP-Binding Proteins | 2005 |
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Farnesyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Mevalonic Acid; Neoplasms; Phosphatidylinositol 3-Kinases; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; ras Proteins | 2005 |
Farnesyltransferase inhibitors in myelodysplastic syndrome.
Topics: Acute Disease; Aged; Alkyl and Aryl Transferases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Hematologic Neoplasms; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Pyridines; Quinolones; Remission Induction; Signal Transduction; Treatment Outcome | 2005 |
Farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Protein Prenylation; Quinolones | 2005 |
Development of farnesyl transferase inhibitors: a review.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins | 2005 |
Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Benzamides; Chronic Disease; Decitabine; Erythropoietin; Humans; Imatinib Mesylate; Piperazines; Primary Myelofibrosis; Pyrimidines; Quinolones; Recombinant Proteins | 2005 |
New drugs in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Thionucleotides | 2003 |
Non-transplant therapy for older adults with acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Aminoglycosides; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cytarabine; Cytogenetic Analysis; Gemtuzumab; Humans; Leukemia, Myeloid; Quinolones | 2006 |
Tipifarnib: farnesyl transferase inhibition at a crossroads.
Topics: Clinical Trials as Topic; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Treatment Outcome | 2006 |
Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Quinolones | 2005 |
[Farnesyl transferase inhibitors--a novel agent for breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Piperidines; Protein Prenylation; Pyridines; Quinolones; ras Proteins | 2006 |
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |
Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biological Availability; Capsules; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Quinolones; Tablets | 2006 |
Farnesyltransferase inihibitors in hematologic malignancies.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Piperidines; Pyridines; Quinolones; Signal Transduction | 2007 |
Clinical activity of tipifarnib in hematologic malignancies.
Topics: Animals; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Myelodysplastic Syndromes; Quinolones | 2007 |
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hematologic Neoplasms; Humans; Pyrazines; Quinolones | 2007 |
Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Clinical Trials as Topic; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Quinolones; Signal Transduction | 2008 |
Novel strategies for patients with chronic myeloproliferative disorders.
Topics: Chronic Disease; Humans; Interferon alpha-2; Interferon-alpha; Janus Kinase 2; Mutation; Myeloproliferative Disorders; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Quinolones; Recombinant Proteins; Thalidomide | 2009 |
Novel therapies for myelodysplastic syndromes.
Topics: Adenine Nucleotides; Aged; Alkylating Agents; Antimetabolites; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; DNA Repair; Drug Therapy, Combination; Drugs, Investigational; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Glutathione; Histone Deacetylase Inhibitors; Humans; Hydrazines; JNK Mitogen-Activated Protein Kinases; Myelodysplastic Syndromes; Quinolones; Sulfonamides; Therapies, Investigational | 2010 |
Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.
Topics: Age Factors; Animals; Antineoplastic Agents; Drug Delivery Systems; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Quinolones | 2010 |
Farnesyltransferase inhibitors in myelodysplastic syndrome.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Farnesyltranstransferase; Gastrointestinal Diseases; Genes, ras; Hematologic Neoplasms; Humans; Middle Aged; Myelodysplastic Syndromes; Piperidines; Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Treatment Outcome | 2006 |
Farnesyltransferase inhibitors: where are we now?
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Neoplasms; Quinolones | 2010 |
Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Topics: Antineoplastic Agents; Biological Products; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Piperidines; Pyridines; Quantitative Structure-Activity Relationship; Quinolones | 2013 |
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Critical Care; Cytarabine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Organophosphates; Quinazolines; Quinolones | 2015 |
Novel therapeutic approaches in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Everolimus; Fusion Proteins, bcr-abl; Gene Expression; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Immunotherapy; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Niacinamide; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinolones; Recombinant Proteins | 2020 |
Concomitant Acute Tubular Necrosis and Acute Interstitial Nephritis Induced by Tipifarnib in a Patient with Squamous Cell Carcinoma of the Lung.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Kidney Cortex Necrosis; Lung Neoplasms; Male; Nephritis, Interstitial; Quinolones | 2021 |
91 trial(s) available for tipifarnib and carbostyril
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
Topics: Administration, Oral; Adult; Aged; Alkyl and Aryl Transferases; Anemia; Biological Availability; Bone Marrow; Capsules; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Half-Life; Headache; Humans; Hypotension; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Peripheral Nervous System Diseases; Quinolones; Solutions; Vomiting | 2000 |
Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Biological Availability; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Quinolones; Time Factors; Vomiting | 2001 |
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Bone Marrow; Cohort Studies; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Prenylation; Quinolones; Recurrence; Remission Induction; Treatment Outcome | 2001 |
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Antineoplastic Agents; Biotransformation; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Genes, ras; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Nausea; Neoplasms; Quinolones; Vomiting | 2002 |
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Blast Crisis; Drug Administration Schedule; Drug Eruptions; Endothelial Growth Factors; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphokines; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Proteins; Primary Myelofibrosis; Quinolones; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Carrier Proteins; Disease Progression; Farnesyltranstransferase; Female; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinolones; Treatment Outcome | 2003 |
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Anemia; Carcinoma, Non-Small-Cell Lung; Disease Progression; Farnesyltranstransferase; Female; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Neutropenia; Quinolones; Survival | 2003 |
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Quinolones; Thrombocytopenia; Treatment Outcome | 2003 |
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Electrolytes; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Mouth Mucosa; Neoplasms; Quinolones; Time Factors | 2003 |
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Topics: Aged; Alkyl and Aryl Transferases; Carrier Proteins; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Quinolones; Remission Induction; Signal Transduction; Treatment Outcome; Tumor Necrosis Factor-alpha | 2003 |
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Models, Chemical; Neoplasms; Protein Prenylation; Quinolones; ras Proteins; Time Factors; Treatment Outcome | 2003 |
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Carrier Proteins; Cell Survival; Disease Progression; DNA-Binding Proteins; Farnesyltranstransferase; Female; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multiple Myeloma; Phosphorylation; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinolones; ras Proteins; Salvage Therapy; Signal Transduction; STAT3 Transcription Factor; Trans-Activators | 2004 |
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Quinolones | 2004 |
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antineoplastic Agents; Enzyme Inhibitors; Farnesyltranstransferase; Feasibility Studies; Female; Fibroblast Growth Factor 2; Genes, ras; Humans; Karyotyping; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Myelodysplastic Syndromes; Quinolones; Treatment Outcome; Vascular Endothelial Growth Factor A | 2004 |
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Treatment Outcome | 2004 |
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Placebos; Prognosis; Quinolones | 2004 |
Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Blood Cell Count; DNA-Binding Proteins; Dose-Response Relationship, Drug; Farnesyltranstransferase; Humans; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinolones; STAT3 Transcription Factor; Trans-Activators; Treatment Outcome | 2004 |
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Humans; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Quinolones; Tandem Repeat Sequences | 2004 |
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Carcinoma, Small Cell; Disease-Free Survival; Farnesyltranstransferase; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinolones; Recurrence; Signal Transduction; Treatment Outcome | 2004 |
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Colorectal Neoplasms; Double-Blind Method; Farnesyltranstransferase; Female; Humans; Male; Middle Aged; Placebos; Quinolones; Survival Rate | 2004 |
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Analysis of Variance; Biological Availability; Blotting, Western; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Risk Assessment; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2004 |
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Dose-Response Relationship, Drug; Exanthema; Farnesyltranstransferase; Fatigue; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Quinolones; Tamoxifen; Treatment Outcome | 2005 |
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; California; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Protein Prenylation; Quinolones | 2005 |
A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Diarrhea; Enzyme Inhibitors; Exanthema; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neutropenia; Prospective Studies; Quinolones; Remission Induction; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2005 |
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Proto-Oncogene Mas; Quinolones; Survival Rate; Treatment Outcome | 2005 |
Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quinolones; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones | 2005 |
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
Topics: Adolescent; Antineoplastic Agents; Bone Marrow; Child; Child, Preschool; Drug Administration Schedule; Drug Eruptions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gastrointestinal Tract; Humans; Male; Neurofibroma, Plexiform; Neurofibromatosis 1; Quinolones; Treatment Outcome | 2006 |
Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Biological Availability; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genotype; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Polymorphism, Genetic; Quinolones; Time Factors | 2006 |
[Farnesyl transferase inhibitors--a novel agent for breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Piperidines; Protein Prenylation; Pyridines; Quinolones; ras Proteins | 2006 |
Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasm Staging; Quinolones; Southwestern United States; Survival Analysis | 2006 |
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Middle Aged; Quinolones; Treatment Outcome | 2006 |
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Induction; Epilepsy; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Quinolones; Treatment Outcome | 2006 |
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Protein Prenylation; Quinolones | 2006 |
Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Female; Glucuronides; Glycoproteins; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Protein Binding; Quinolones; Serum Albumin; Tablets; Treatment Outcome | 2006 |
Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function.
Topics: Adult; Aged; Area Under Curve; Farnesyltranstransferase; Female; Humans; Liver; Male; Middle Aged; Models, Statistical; Neoplasms; Neutrophils; Quinolones; Time Factors | 2006 |
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Farnesyltranstransferase; Female; HSP40 Heat-Shock Proteins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Quinolones; Remission Induction; Risk; Survival Rate; Treatment Outcome | 2007 |
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Farnesyltranstransferase; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Quinolones; Risk; Survival Analysis; Treatment Outcome | 2007 |
E2902: A Phase III randomized study of farnesyl transferase inhibitor R115777 in acute myeloid leukemia patients in second or subsequent remission or in remission after primary induction failure or patients over age 60 in first remission.
Topics: Aged; Antineoplastic Agents; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Salvage Therapy | 2007 |
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Bone Marrow Cells; Farnesyltranstransferase; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Quinolones; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |
Exposure-toxicity relationships for tipifarnib in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Male; Middle Aged; Quinolones; Treatment Outcome | 2007 |
Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests; Quinolones; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Female; Humans; Immune System; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Taxoids; Treatment Outcome | 2007 |
Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinolones; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Conformal | 2007 |
A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Bone Marrow; Female; Humans; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinolones; Thrombocythemia, Essential; Treatment Outcome | 2007 |
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maximum Tolerated Dose; Middle Aged; Piperazines; Pyrimidines; Quinolones | 2007 |
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Estrogen Receptor Modulators; Farnesyltranstransferase; Female; Humans; Letrozole; Middle Aged; Nitriles; Quinolones; Time Factors; Treatment Outcome; Triazoles | 2008 |
A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem Neoplasms; Child; Child, Preschool; Disease Progression; Female; Glioma; Humans; Male; Medulloblastoma; Neuroectodermal Tumors; Quinolones; Treatment Outcome | 2007 |
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; DNA-Binding Proteins; Farnesyltranstransferase; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Guanine Nucleotide Exchange Factors; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nuclear Proteins; Prognosis; Proportional Hazards Models; Quinolones; Recurrence; Reproducibility of Results; Survival Analysis | 2008 |
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Drug Administration Schedule; Farnesyltranstransferase; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Quinolones | 2008 |
Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Quinolones; Radiotherapy | 2008 |
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinolones; Remission Induction; Risk Factors; Treatment Outcome | 2008 |
Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Double-Blind Method; Europe; Female; Gemcitabine; Humans; Incidence; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Pain Measurement; Pancreatic Neoplasms; Patient Satisfaction; Placebo Effect; Quinolones; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; United States | 2009 |
Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm, Residual; Neurosurgical Procedures; Quinolones; Radiotherapy | 2008 |
A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug-Related Side Effects and Adverse Reactions; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Quinolones; Remission Induction | 2009 |
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Topics: Administration, Oral; Age of Onset; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Myeloid, Acute; Quinolones; Tumor Cells, Cultured; U937 Cells | 2009 |
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Farnesyltranstransferase; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Quinolones; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2009 |
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Farnesyltranstransferase; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Quinolones; rho GTP-Binding Proteins; STAT3 Transcription Factor | 2009 |
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Neutropenia; Quinolones; Survival Rate; Time Factors | 2009 |
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Farnesyltranstransferase; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Treatment Outcome | 2009 |
Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.
Topics: A Kinase Anchor Proteins; Administration, Oral; Aged; Antineoplastic Agents; DNA-Binding Proteins; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Lymphoma, Mantle-Cell; Male; Minor Histocompatibility Antigens; Neoplasm Recurrence, Local; Nuclear Proteins; Predictive Value of Tests; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Treatment Outcome | 2010 |
Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Farnesyltranstransferase; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Protein Array Analysis; Quinolones; Tamoxifen | 2010 |
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Farnesyltranstransferase; Female; Half-Life; Humans; Infant; Leukemia; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Quinolones | 2011 |
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Quinolones; Temozolomide | 2011 |
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Age of Onset; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoadjuvant Therapy; Neoplasm Staging; Quinolones; Remission Induction; Risk; Young Adult | 2011 |
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones | 2011 |
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Neuroendocrine; Cell Differentiation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Female; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Niacinamide; Oncogene Protein p21(ras); Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; raf Kinases; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2011 |
Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Pons; Quinolones; Radiotherapy Dosage; Survival Rate; Tissue Distribution; Treatment Outcome; Young Adult | 2011 |
A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Quinolones; Recurrence; Risk Factors | 2011 |
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lymphoma; Male; Middle Aged; Quinolones; Recurrence; Treatment Outcome; Young Adult | 2011 |
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA-Binding Proteins; Etoposide; Female; Follow-Up Studies; Guanine Nucleotide Exchange Factors; Humans; Leukemia, Myeloid, Acute; Male; Nuclear Proteins; Pharmacogenetics; Prognosis; Quinolones; Remission Induction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate | 2012 |
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome | 2012 |
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Quinolones; Taxoids; Treatment Outcome | 2012 |
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinolones; Survival Analysis; Treatment Outcome | 2012 |
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Female; HSP40 Heat-Shock Proteins; Humans; Interferon-gamma; Male; Melanoma; Middle Aged; Neoplasm Staging; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinolones; Signal Transduction; Skin Neoplasms; T-Lymphocytes; Treatment Outcome | 2012 |
αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Brain Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Fibroblast Growth Factor 2; Focal Adhesion Kinase 1; Glioblastoma; Humans; Integrin alphaVbeta3; Male; Middle Aged; Protein Serine-Threonine Kinases; Quinolones; Radiation-Sensitizing Agents; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Vitronectin; Treatment Outcome | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid | 2013 |
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Farnesyl-Diphosphate Farnesyltransferase; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Quinolones; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2013 |
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
Topics: Administration, Oral; Aged; Aged, 80 and over; Drug Administration Schedule; Farnesyltranstransferase; Female; Humans; Leukemia, Myeloid, Acute; Male; Quinolones; Remission Induction; Survival Rate; Treatment Outcome | 2014 |
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Cross-Over Studies; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Neurofibroma, Plexiform; Neurofibromatosis 1; Quinolones; Treatment Outcome; Young Adult | 2014 |
Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; Choline; Creatine; Female; Glioblastoma; Humans; Lactic Acid; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Radiotherapy, Conformal; Sensitivity and Specificity | 2014 |
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Isotretinoin; Leukemia, Myelomonocytic, Juvenile; Male; Middle Aged; Quinolones; Survival Rate; Vidarabine | 2015 |
Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cerebrovascular Circulation; Contrast Media; Female; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Quinolones; Radiotherapy; Survival Analysis; Treatment Outcome | 2015 |
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Sorafenib; Treatment Outcome | 2018 |
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Quinolones; Treatment Outcome | 2018 |
A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Quinolones; Salvage Therapy; Tissue Distribution | 2019 |
Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Male; Mice; Middle Aged; Proto-Oncogene Proteins p21(ras); Quinolones; RNA-Seq; Single-Cell Analysis; Transcriptome; Treatment Failure; Tumor Microenvironment; Urinary Bladder Neoplasms | 2020 |
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Quinolones; Salivary Gland Neoplasms; Treatment Outcome | 2020 |
A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring
Topics: Aged; AMP-Activated Protein Kinase Kinases; Carcinoma; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Progression-Free Survival; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Quinolones; Urothelium | 2020 |
A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Quinolones; Treatment Outcome | 2021 |
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
Topics: Antineoplastic Agents; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Quinolones; Salvage Therapy; Survival Rate | 2021 |
137 other study(ies) available for tipifarnib and carbostyril
| Article | Year |
|---|---|
Clinical trials referral resource. Clinical trials with the farnesyl transferase inhibitor R115777.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Clinical Trials as Topic; Farnesyltranstransferase; Humans; Neoplasms; Quinolones | 1999 |
Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
Topics: 3T3 Cells; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Cell Line, Transformed; Enzyme Inhibitors; Female; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Protein Prenylation; Quinolones; ras Proteins; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells.
Topics: 3T3 Cells; Animals; Benzoquinones; Biomarkers, Tumor; Cell Division; Cell Line, Transformed; Enzyme Inhibitors; Genes, ras; Lactams, Macrocyclic; Magnetic Resonance Spectroscopy; MAP Kinase Signaling System; Mice; Mutation; Nucleotides; Phosphorylcholine; Proto-Oncogene Proteins p21(ras); Quinolones; Rifabutin; Simvastatin; Transfection | 2001 |
Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; HT29 Cells; Humans; Immunohistochemistry; Ki-67 Antigen; Lamin Type A; Mice; Mice, Nude; Neoplasm Transplantation; Nuclear Proteins; Protein Precursors; Quinolones; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis.
Topics: Alendronate; Alkyl and Aryl Transferases; Animals; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; Flow Cytometry; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Quinolones; Tumor Cells, Cultured | 2002 |
Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Blotting, Western; Cell Division; Chromones; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Farnesyltranstransferase; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Quinazolines; Quinolones; Transfection; Tumor Cells, Cultured | 2002 |
Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a farnesyl
Topics: Adult; Alkyl and Aryl Transferases; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Male; Mass Spectrometry; Particle Accelerators; Quinolones | 2002 |
Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.
Topics: Alkyl and Aryl Transferases; Cell Death; Cell Survival; Enzyme Inhibitors; Farnesyltranstransferase; Gene Expression; Genes, ras; Glioma; Humans; Mutation; Quinolones; Radiation-Sensitizing Agents; ras Proteins; rhoB GTP-Binding Protein; Transfection; Tumor Cells, Cultured | 2002 |
Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra).
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Disease Models, Animal; Humans; Mice; Neoplasms; Quinolones; Transplantation, Heterologous | 2002 |
Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.
Topics: Aged; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; Cell Division; DNA-Binding Proteins; Enzyme Inhibitors; Farnesyltranstransferase; Female; Flow Cytometry; Humans; Interleukin-6; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multiple Myeloma; Protein Prenylation; Quinolones; STAT3 Transcription Factor; Trans-Activators; Tumor Cells, Cultured | 2002 |
Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Piperidines; Pyridines; Quinolones | 2002 |
[New data presented at ASCO 2002 concerning small cell bronchial cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Quinolones; Smoking; Smoking Prevention; Survival Analysis; Treatment Outcome | 2002 |
5-imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Azepines; Farnesyltranstransferase; Humans; In Vitro Techniques; Indicators and Reagents; Mice; Microsomes, Liver; Quinazolines; Quinolones; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2003 |
Molecular targeting therapy for cancer: the Twelfth International Symposium of the Hiroshima Cancer Seminar, November 2002.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials as Topic; DNA Repair; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Farnesyltranstransferase; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Proteins; Neoplasms; Quinolones; Xenograft Model Antitumor Assays | 2003 |
Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzo(a)pyrene; Chemoprevention; Enzyme Inhibitors; Female; Lung Neoplasms; Mice; Mice, Inbred A; Quinolones | 2003 |
In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cell Survival; Cells, Cultured; Chromones; Colony-Forming Units Assay; Enzyme Inhibitors; Erythrocyte Count; Farnesyltranstransferase; Female; Flavonoids; GPI-Linked Proteins; Hematopoietic Stem Cells; Humans; Male; Membrane Glycoproteins; Mesothelin; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Proteins; Quinolones; Thrombocythemia, Essential | 2003 |
Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Cell Separation; Dose-Response Relationship, Drug; Farnesyltranstransferase; Humans; Multiple Myeloma; Mutation; Quinolones; ras Proteins; Tumor Cells, Cultured | 2003 |
Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.
Topics: Alkyl and Aryl Transferases; Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Adhesion; Cell Cycle; Cell Movement; Colony-Forming Units Assay; Enzyme Inhibitors; Farnesyltranstransferase; Hematopoiesis; Humans; Leukemia; Mice; Mice, Inbred NOD; Mice, SCID; Poly(ADP-ribose) Polymerases; Quinolones; Time Factors; Tumor Cells, Cultured | 2003 |
Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Farnesyltranstransferase; Humans; Imidazoles; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperidines; Pyridines; Quinolones | 2003 |
4-methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Cell Division; Enzyme Inhibitors; Farnesyltranstransferase; Heterocyclic Compounds; Humans; Kinetics; Mice; Microsomes, Liver; Models, Molecular; Molecular Conformation; Quinolones; Structure-Activity Relationship; Triazoles | 2003 |
Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors.
Topics: Alkyl and Aryl Transferases; Animals; Cell Division; Drug Design; Enzyme Inhibitors; Farnesyltranstransferase; Kinetics; Molecular Conformation; Molecular Structure; Quinazolines; Quinolines; Quinolones; Structure-Activity Relationship | 2003 |
The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Cell Hypoxia; Enzyme Inhibitors; Farnesyltranstransferase; Glioblastoma; Glioma; Humans; Immunoenzyme Techniques; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neovascularization, Pathologic; Oxygen; Quinolones; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Caspase 9; Caspase Inhibitors; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Division; Cell Line, Tumor; Humans; Intracellular Membranes; Membrane Potentials; Membrane Proteins; Mitochondria; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protein Prenylation; Proto-Oncogene Proteins c-bcl-2; Quinolones; ras Proteins; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Signal Transduction; Transcription Factor CHOP; Transcription Factors | 2004 |
Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.
Topics: Alkyl and Aryl Transferases; Animals; Benzodiazepines; Crystallization; Crystallography, X-Ray; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Quinolones; Rats; Structure-Activity Relationship; Substrate Specificity | 2004 |
Influence of farnesyl transferase inhibitor treatment on epidermal growth factor receptor status.
Topics: Alkyl and Aryl Transferases; Animals; Cell Line; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Farnesyltranstransferase; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neoplasm Transplantation; Quinolones; Radiopharmaceuticals; Regression Analysis; Tissue Distribution | 2004 |
The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.
Topics: Alkyl and Aryl Transferases; Apoptosis; Caspases; Cell Division; Diphosphonates; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; Farnesyltranstransferase; Humans; Imidazoles; KB Cells; Mitogen-Activated Protein Kinases; Pamidronate; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinolones; Zoledronic Acid | 2004 |
Quantile estimation following non-parametric phase I clinical trials with ordinal response.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Computer Simulation; Data Interpretation, Statistical; Humans; Leukemia; Maximum Tolerated Dose; Quinolones; Regression Analysis; Statistics, Nonparametric | 2004 |
Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia.
Topics: Acute Disease; Alkyl and Aryl Transferases; Apoptosis; Cell Growth Processes; Farnesyltranstransferase; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Myeloid; Oligonucleotide Array Sequence Analysis; Quinolones | 2004 |
Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor.
Topics: Alkyl and Aryl Transferases; Animals; Calcium; Cell Line; Cell Survival; Cyclic AMP; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Iloprost; Ireland; Mice; Molecular Chaperones; Organophosphonates; Protein Prenylation; Quinolones; Receptor Cross-Talk; Receptors, Prostaglandin; Time Factors; Transfection; Transferases; Tritium | 2004 |
Design, synthesis, and activity of 4-quinolone and pyridone compounds as nonthiol-containing farnesyltransferase inhibitors.
Topics: 4-Quinolones; Alkyl and Aryl Transferases; Crystallography, X-Ray; Farnesyltranstransferase; Models, Molecular; Pyridones; Quinolones; Structure-Activity Relationship | 2004 |
Synthesis and activity of 1-aryl-1'-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Cell Line, Transformed; Crystallography, X-Ray; Ethers; Farnesyltranstransferase; Genes, ras; Humans; Imidazoles; Mice; Models, Molecular; NIH 3T3 Cells; Quinolones; Structure-Activity Relationship | 2004 |
The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cladribine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Leukemia, Myeloid; Male; Middle Aged; Quinolones; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vidarabine | 2004 |
Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells.
Topics: Alkyl and Aryl Transferases; Case-Control Studies; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; Farnesyltranstransferase; Humans; Polycythemia Vera; Quinolones | 2005 |
The American Society of Hematology--46th Annual Meeting and Exposition. HDAC, Flt and farnesyl transferase inhibitors.
Topics: Alkyl and Aryl Transferases; Carbazoles; Farnesyltranstransferase; fms-Like Tyrosine Kinase 3; Furans; Hematology; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Indoles; Panobinostat; Proto-Oncogene Proteins; Quinolones; Receptor Protein-Tyrosine Kinases; Societies, Medical; United States | 2005 |
Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor.
Topics: Alkyl and Aryl Transferases; Animals; Biomarkers, Tumor; Cell Line, Tumor; Colonic Neoplasms; Epidermal Growth Factor; ErbB Receptors; Farnesyltranstransferase; Humans; Male; Metabolic Clearance Rate; Mice; Organ Specificity; Organotechnetium Compounds; Quinolones; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution; Treatment Outcome | 2005 |
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow Cells; Caspase 3; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials as Topic; Cytochromes c; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Enzyme Activation; Farnesyltranstransferase; Flow Cytometry; Fluorouracil; G2 Phase; Gemcitabine; Homozygote; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Mice; Mice, SCID; Mitosis; Multiple Myeloma; Paclitaxel; Quinolones; Taxoids; Tetrazolium Salts; Thiazoles | 2005 |
Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.
Topics: Adenocarcinoma; Alkyl and Aryl Transferases; Cell Cycle Proteins; Cell Growth Processes; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Humans; Interleukin-6; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-myc; Quinolones; Serine; STAT3 Transcription Factor; Trans-Activators; Tyrosine; Up-Regulation | 2005 |
In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy.
Topics: Adenocarcinoma; Alkyl and Aryl Transferases; Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Farnesyltranstransferase; Humans; Iodine Radioisotopes; Male; Mice; Mice, Nude; Prognosis; Quinolones; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2005 |
[New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].
Topics: Acute Disease; Antineoplastic Agents; Carbazoles; Furans; Humans; Indoles; Leukemia; Leukemia, Myeloid, Acute; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Quinolones; ras Proteins; Staurosporine | 2005 |
Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Cell Line, Tumor; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Quinolones | 2005 |
Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity.
Topics: Alkyl and Aryl Transferases; Animals; Benzimidazoles; Enzyme Inhibitors; Farnesyltranstransferase; Indoles; Mice; NIH 3T3 Cells; Quinolones | 2005 |
Molecule of the month. Tipifarnib.
Topics: Acute Disease; Aged; Antineoplastic Agents; Clinical Trials as Topic; Humans; Leukemia, Myeloid; Quinolones | 2005 |
Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Docetaxel; Drug Synergism; Enzyme Inhibitors; Epithelial Cells; Farnesyltranstransferase; Genes, p53; Humans; Mitogen-Activated Protein Kinase 3; Quinolones; ras Proteins; Taxoids; Tumor Cells, Cultured | 2005 |
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
Topics: Adolescent; Antineoplastic Agents; Biomarkers, Tumor; Child; Child, Preschool; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Farnesyltranstransferase; Female; Humans; Leukemia, Monocytic, Acute; Male; Mutation; Oncogene Protein p21(ras); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinolones; Tumor Cells, Cultured | 2005 |
The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease.
Topics: Alkyl and Aryl Transferases; Animals; Binding Sites; Chagas Disease; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Lanosterol; Models, Molecular; Oxidoreductases; Protein Binding; Quinolones; Sterol 14-Demethylase; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma cruzi | 2005 |
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin | 2005 |
Farnesyltransferase inhibitors.
Topics: Acylation; Aged; Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Middle Aged; Neoplasm Proteins; Neoplasms; Protein Processing, Post-Translational; Quinolones; ras Proteins; Treatment Outcome | 2005 |
Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
Topics: Amino Acid Motifs; Blotting, Western; Cell Nucleus; Fibroblasts; Green Fluorescent Proteins; HeLa Cells; Humans; Lamin Type A; Lipoproteins; Membrane Proteins; Metalloendopeptidases; Metalloproteases; Mutation; Nuclear Proteins; Progeria; Protein Precursors; Protein Prenylation; Quinolones | 2005 |
Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Farnesyltranstransferase; Humans; Multiple Myeloma; Quinolones; Tumor Cells, Cultured | 2005 |
Farnesyl transferase inhibition in hematologic malignancies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Quinolones | 2005 |
Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib.
Topics: Animals; Anti-Inflammatory Agents; Cell Line, Tumor; Cytokines; Dose-Response Relationship, Drug; Farnesyltranstransferase; Humans; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Microarray Analysis; Quinolones; Signal Transduction; Transcription, Genetic | 2006 |
Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets.
Topics: Alkylating Agents; Animals; Farnesyltranstransferase; Female; Gene Expression; Genes, ras; Mammary Neoplasms, Experimental; Methylnitrosourea; Mutation; Oligonucleotide Array Sequence Analysis; Quinolones; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fibronectins; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Pyrazines; Quinolones; Stromal Cells; Tumor Cells, Cultured | 2006 |
Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Female; Humans; Pyrrolidines; Quinolones; Receptors, Estrogen; Tamoxifen | 2005 |
Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.
Topics: Animals; Breast Neoplasms; Calcinosis; Carcinoma, Intraductal, Noninfiltrating; Cell Division; Cell Line, Tumor; Farnesyltranstransferase; Female; Humans; Mammography; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Quinolones; Transplantation, Heterologous | 2006 |
Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations.
Topics: Animals; Anticarcinogenic Agents; Antimutagenic Agents; Apoptosis; Carcinogens; Cell Division; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Mammary Neoplasms, Experimental; Methylnitrosourea; Quinolones; Rats; Rats, Sprague-Dawley | 2006 |
Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT).
Topics: Animals; Anti-Inflammatory Agents; Budesonide; Disease Models, Animal; DNA Methylation; Drug Therapy, Combination; Female; Lung Neoplasms; Mice; Mice, Inbred A; Quinolones | 2006 |
HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway.
Topics: Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Enzyme Inhibitors; Farnesyltranstransferase; Glioblastoma; HSP40 Heat-Shock Proteins; Humans; Quinolones; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53 | 2006 |
Depletion of substrates for protein prenylation increases apoptosis in human periovulatory granulosa cells.
Topics: Apoptosis; Cells, Cultured; Cholesterol; Diterpenes; Estrenes; Farnesol; Farnesyltranstransferase; Female; Furans; Granulosa Cells; Hormone Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Leucine; Mifepristone; Ovulation; Protein Prenylation; Quinolones; Receptors, Progesterone | 2006 |
Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (Zarnestra MT).
Topics: Animals; Anti-Inflammatory Agents; Budesonide; Chemoprevention; Disease Models, Animal; DNA Methylation; Drug Therapy, Combination; Female; Lung Neoplasms; Mice; Mice, Inbred A; Quinolones; Urethane | 2007 |
R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; Caspases; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinolones; ras Proteins; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays; Zoledronic Acid | 2007 |
The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cell Line, Tumor; Clone Cells; Farnesyltranstransferase; Humans; Leukemia-Lymphoma, Adult T-Cell; Quinolones; Verapamil | 2007 |
[Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biomarkers, Tumor; Child; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Loss of Heterozygosity; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Rituximab; Tretinoin | 2007 |
Impact on farnesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zarnestra series.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Farnesyltranstransferase; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Quinolones | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinolones; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2007 |
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.
Topics: Antibodies, Monoclonal; Blotting, Western; CD28 Antigens; CD3 Complex; Cells, Cultured; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; HSP40 Heat-Shock Proteins; Humans; Interferon-gamma; Interleukin-2; Interleukin-4; Lymphocyte Activation; MAP Kinase Kinase 4; Methionine; Phosphorylation; Piperidines; Protein Prenylation; Pyridines; Quinolones; Ribonuclease, Pancreatic; Ribosomal Protein S6 Kinases, 70-kDa; RNA Processing, Post-Transcriptional; T-Lymphocytes; Th1 Cells; Th2 Cells | 2007 |
Massive plexiform neurofibromas in childhood: natural history and management issues.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cyclophosphamide; Humans; Magnetic Resonance Imaging; Male; Neoplasms, Second Primary; Neurofibroma, Plexiform; Neurosurgical Procedures; Pain; Quinolones; Respiration Disorders; Retrospective Studies | 2007 |
Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Farnesyltranstransferase; Female; Humans; Lamin Type A; Lymphoma, Mantle-Cell; Mice; Mice, Nude; Nuclear Proteins; Protein Precursors; Quinolones; Xenograft Model Antitumor Assays | 2008 |
Cloning and characterization of a human BCR/ABL-positive cell line, K562/RR, resistant to the farnesyltransferase inhibition by tipifarnib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cloning, Molecular; Drug Resistance, Neoplasm; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; K562 Cells; Quinolones | 2007 |
The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Farnesyltranstransferase; Female; Humans; Immunohistochemistry; Interferon-alpha; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasms; Phosphoserine; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Quinolones; ras Proteins; Signal Transduction; Xenograft Model Antitumor Assays | 2007 |
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Drug Therapy, Combination; Farnesyltranstransferase; Female; Flow Cytometry; Fluorescent Antibody Technique; G1 Phase; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; Quinolones; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transplantation, Heterologous | 2007 |
Tipifarnib in acute myeloid leukemia.
Topics: Antineoplastic Agents; Controlled Clinical Trials as Topic; Drug Delivery Systems; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Quinolones | 2007 |
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Cell Line, Tumor; Exons; Humans; Male; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Thyroid Neoplasms | 2008 |
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Diagnosis, Differential; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib | 2008 |
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Checkpoint Kinase 1; DNA Damage; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Multiple Myeloma; Protein Kinase Inhibitors; Protein Kinases; Quinolones; ras Proteins; Staurosporine; Xenograft Model Antitumor Assays | 2008 |
Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling.
Topics: Antineoplastic Agents; Cells, Cultured; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Hypertension, Pulmonary; K562 Cells; Leukemia, Large Granular Lymphocytic; Middle Aged; Quinolones; Receptors, Natural Killer Cell; Signal Transduction; Treatment Outcome | 2008 |
In vitro effects of the farnesyltransferase inhibitor tipifarnib on myelodysplastic syndrome progenitors.
Topics: Aged; Apoptosis; Colony-Forming Units Assay; Enzyme Inhibitors; Farnesyltranstransferase; Female; Hematopoiesis; Humans; Immunomagnetic Separation; In Vitro Techniques; Male; Middle Aged; Myelodysplastic Syndromes; Myeloid Progenitor Cells; Neoplastic Stem Cells; Quinolones | 2008 |
A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model.
Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Mice; Progeria; Quinolones | 2008 |
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Synthesis and structure-activity relationships of novel benzofuran farnesyltransferase inhibitors.
Topics: Animals; Antineoplastic Agents; Benzofurans; Chemistry, Pharmaceutical; Crystallography, X-Ray; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Inhibitory Concentration 50; Mice; Neoplasm Transplantation; Quinolones; Structure-Activity Relationship | 2009 |
Rational modification of a candidate cancer drug for use against Chagas disease.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Chagas Disease; Humans; Mice; Mice, Inbred BALB C; Models, Molecular; Quinolones; Rats; Trypanocidal Agents | 2009 |
Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzene; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Drug Therapy, Combination; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Male; Occupational Exposure; Platelet Count; Quinolones; Thalidomide; Valproic Acid | 2009 |
Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples.
Topics: Anticholesteremic Agents; Antigens, CD34; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Therapy, Combination; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin | 2009 |
W7FW14F apomyoglobin amyloid aggregates-mediated apoptosis is due to oxidative stress and AKT inactivation caused by Ras and Rac.
Topics: Amyloid; Animals; Apoproteins; Apoptosis; Benzamides; Cell Line; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Mice; Microscopy, Fluorescence; Mitochondria; Models, Biological; Mutant Proteins; Myoglobin; Oxidative Stress; Protein Structure, Quaternary; Proto-Oncogene Proteins c-akt; Quinolones; rac GTP-Binding Proteins; ras Proteins | 2009 |
Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents.
Topics: Animals; Antineoplastic Agents; Chagas Disease; Drug Evaluation, Preclinical; Mice; Molecular Conformation; Parasitic Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma cruzi | 2009 |
[Targeting KRAS pathway in NSCLC therapy].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Farnesyltranstransferase; Genes, ras; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Quinolones; raf Kinases; ras Proteins; Sorafenib | 2009 |
Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leukemia; Quinolones; Signal Transduction; Sirolimus; Tumor Cells, Cultured | 2010 |
Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected].
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Male; Osteosarcoma; Quinolones; ras Proteins; U937 Cells; Up-Regulation | 2010 |
Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib.
Topics: Antineoplastic Agents; Child; Female; Humans; In Vitro Techniques; Neurofibromin 1; Polymorphism, Single Nucleotide; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Quinolones; Sequence Deletion | 2010 |
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.
Topics: 3T3 Cells; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Chagas Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Isoenzymes; Mice; Models, Molecular; Protein Binding; Quinolones; Rats; Sterol 14-Demethylase; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma cruzi | 2010 |
Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Monomeric GTP-Binding Proteins; Multiprotein Complexes; Mutation; Neuropeptides; Phosphorylation; Piperidines; Prenylation; Proteins; Pyridines; Quinolones; Ras Homolog Enriched in Brain Protein; Ribosomal Protein S6; RNA Interference; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Transfection | 2010 |
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Quinolones; Ubiquitination | 2010 |
DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium.
Topics: Adolescent; Anisotropy; Antineoplastic Agents; Brain Stem; Brain Stem Neoplasms; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Diffusion Tensor Imaging; Gefitinib; Glioma; Humans; Image Interpretation, Computer-Assisted; Male; Nerve Fibers, Myelinated; Quinazolines; Quinolones; Radiotherapy | 2011 |
MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Diffusion; Female; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Quinazolines; Quinolones; Radiotherapy Dosage; Research Design; Survival Rate; Treatment Outcome | 2011 |
Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Calcium Channels; Cell Membrane; Endoplasmic Reticulum; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinolones; Tumor Cells, Cultured; U937 Cells | 2011 |
Novel agents for the treatment of acute myeloid leukemia in the older patient.
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide | 2011 |
The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.
Topics: Acyclic Monoterpenes; Alendronate; Animals; Anti-Inflammatory Agents; Cell Line; Child; Child, Preschool; Cholesterol; Cytokines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Inflammation Mediators; Lovastatin; Male; Mevalonate Kinase Deficiency; Mice; Monocytes; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Polyenes; Polyisoprenyl Phosphates; Polyunsaturated Alkamides; Pyridines; Quinolones; Terpenes | 2011 |
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom | 2011 |
Tipifarnib-mediated suppression of T-bet-dependent signaling pathways.
Topics: Acetylation; Adult; Aged; Antineoplastic Agents; Cytokines; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Humans; Immunosuppression Therapy; Leukemia, Large Granular Lymphocytic; Male; Middle Aged; Quinolones; Signal Transduction; T-Box Domain Proteins; Th1 Cells; Th1-Th2 Balance; Th2 Cells | 2012 |
Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Blotting, Western; Caspase 3; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; In Situ Nick-End Labeling; Lactams, Macrocyclic; Protein Serine-Threonine Kinases; Quinolones; U937 Cells | 2012 |
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Quinolones; Remission Induction; Retrospective Studies; Treatment Outcome | 2012 |
Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Synergism; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Quinolones; ras Proteins; Signal Transduction; Taxoids | 2013 |
Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib.
Topics: 14-alpha Demethylase Inhibitors; Administration, Oral; Alkyl and Aryl Transferases; Animals; Chagas Disease; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Female; Humans; Mice; Models, Molecular; Nitroimidazoles; Quinolones; Structure-Activity Relationship; Triazoles; Trypanocidal Agents; Trypanosoma cruzi | 2012 |
Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells.
Topics: Animals; Bone Marrow Transplantation; CD4-Positive T-Lymphocytes; Graft vs Host Disease; Graft vs Leukemia Effect; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Prenylation; Protein Prenylation; Quinolones; Treatment Outcome | 2013 |
Quantitative structure-activity relationships of imidazole-containing farnesyltransferase inhibitors using different chemometric methods.
Topics: Antineoplastic Agents; Farnesyltranstransferase; Humans; Imidazoles; Inhibitory Concentration 50; Models, Biological; Molecular Structure; Quantitative Structure-Activity Relationship; Quinolones; Software | 2013 |
Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.
Topics: ADP-ribosyl Cyclase 1; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Histones; Humans; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Nuclear Proteins; Nucleophosmin; Quinolones; Sialic Acid Binding Ig-like Lectin 3; Signal Transduction | 2012 |
Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung; Lung Neoplasms; MAP Kinase Signaling System; Phosphorylation; Quinolones; Simvastatin | 2012 |
Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice.
Topics: Animals; Aorta; Apolipoproteins E; Apoptosis; Atherosclerosis; Blood Proteins; Body Weight; Collagen Type I; Enzyme Inhibitors; Farnesyltranstransferase; Female; Kidney Failure, Chronic; Liver; Macrophages; Mevalonic Acid; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Prenylation; Quinolones; Random Allocation; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tyrosine; Uremia; Vascular Calcification | 2013 |
Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Monomeric GTP-Binding Proteins; Neuropeptides; Prenylation; Protein Stability; Proto-Oncogene Proteins; Quinolones; Ras Homolog Enriched in Brain Protein; Signal Transduction; TOR Serine-Threonine Kinases; U937 Cells | 2014 |
Tanespimycin and tipifarnib exhibit synergism in inducing apoptosis in melanoma cell lines from later stages of tumor progression.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Melanoma; Protein Serine-Threonine Kinases; Quinolones | 2013 |
Temperature and drug treatments in mevalonate kinase deficiency: an ex vivo study.
Topics: Acyclic Monoterpenes; Anti-Inflammatory Agents; Apoptosis; Biosynthetic Pathways; Carrier Proteins; Child; Cytokines; Female; Humans; Inflammasomes; Interleukin-1beta; Lipopolysaccharides; Male; Mevalonate Kinase Deficiency; Mevalonic Acid; NLR Family, Pyrin Domain-Containing 3 Protein; Quinolones; Temperature; Terpenes | 2013 |
In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida.
Topics: Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Microbial Sensitivity Tests; Polyenes; Polyunsaturated Alkamides; Quinolones | 2013 |
Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design.
Topics: Antifungal Agents; Aspergillus fumigatus; Benzenesulfonamides; Catalytic Domain; Crystallography, X-Ray; Drug Design; Farnesyltranstransferase; Fungal Proteins; Humans; Peptides; Polyisoprenyl Phosphates; Protein Conformation; Protein Structure, Secondary; Protein Structure, Tertiary; Quinolones; Sesquiterpenes; Sulfonamides | 2014 |
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Female; Heptanoic Acids; Humans; Injections, Intraperitoneal; Mice; Mice, SCID; Neoplasms, Experimental; Pancreatic Neoplasms; Pyrazoles; Pyrroles; Quinolones; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Plexiform neurofibromas, trial design, and the definitions of "progression" and "treatment failure".
Topics: Antineoplastic Agents; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Neurofibroma, Plexiform; Neurofibromatosis 1; Quinolones | 2014 |
Farnesyltransferase inhibitor, tipifarnib, prevents galactosamine/lipopolysaccharide-induced acute liver failure.
Topics: Animals; Caspase 3; Cell Survival; Cytokines; Endotoxemia; Enzyme Inhibitors; Farnesyltranstransferase; Galactosamine; Gene Expression Regulation; Hepatocytes; Inflammation; Interleukin-6; Lipids; Lipopolysaccharides; Liver; Liver Failure, Acute; Male; Mice; Mice, Inbred C57BL; Quinolones; Sepsis; Tumor Necrosis Factor-alpha | 2014 |
Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukemia; Quinolones; ras Proteins; Simvastatin | 2014 |
Effect of Farnesyltransferase Inhibitor R115777 on Mitochondria of Plasmodium falciparum.
Topics: Antimalarials; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Malaria, Falciparum; Mitochondria; Plasmodium falciparum; Protozoan Proteins; Quinolones | 2015 |
HIV-infected CD4+ T Cells Use T-bet-dependent Pathway for Production of IL-10 Upon Antigen Recognition.
Topics: Adult; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cells, Cultured; Cyclosporine; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; Forkhead Transcription Factors; HIV Core Protein p24; HIV Infections; Humans; Interferon-gamma; Interleukin-10; Lymphocyte Activation; Male; Middle Aged; Quinolones; T-Box Domain Proteins; Young Adult | 2016 |
Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1α and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro.
Topics: Cadherins; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Quinolones; Receptors, Estrogen; Signal Transduction; Triple Negative Breast Neoplasms | 2017 |
Increased susceptibility to oxidative stress- and ultraviolet A-induced apoptosis in fibroblasts in atypical progeroid syndrome/atypical Werner syndrome with LMNA mutation.
Topics: Amino Acid Substitution; Apoptosis; Cells, Cultured; Enzyme Inhibitors; Farnesyltranstransferase; Fibroblasts; Humans; Hydrogen Peroxide; Lamin Type A; Mutation, Missense; Necrosis; Oxidative Stress; Quinolones; Skin; Ultraviolet Rays; Werner Syndrome | 2016 |
Tipifarnib prevents development of hypoxia-induced pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Hypertension, Pulmonary; Hypoxia; Male; Mice, Inbred C57BL; Phenotype; Protein Prenylation; Proteomics; Pulmonary Artery; Quinolones; rhoB GTP-Binding Protein; Time Factors; Transfection; Vasoconstriction; Vasodilation | 2017 |
Farnesylation of RhoB: the cancer hypothesis of pulmonary hypertension revisited.
Topics: Humans; Hypertension, Pulmonary; Hypoxia; Neoplasms; Prenylation; Quinolones; rhoB GTP-Binding Protein | 2017 |
The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Gene Expression Regulation, Neoplastic; Humans; Mutation; Piperazines; Proto-Oncogene Proteins p21(ras); Pyridines; Quinolones; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Tumor Cells, Cultured | 2019 |
Comparative toxicity evaluation of targeted anticancer therapeutics in embryonic zebrafish and sea urchin models.
Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents; Arbacia; Benzamides; Cell Proliferation; Dose-Response Relationship, Drug; Embryonic Development; Enzyme Inhibitors; Molecular Targeted Therapy; Morpholines; Oxadiazoles; Pyrimidines; Quinolones; Signal Transduction; Wortmannin; Zebrafish | 2018 |
The farnesyltransferase β-subunit RAM1 regulates localization of RAS proteins and appressorium-mediated infection in Magnaporthe oryzae.
Topics: Farnesyltranstransferase; Fungal Proteins; Gene Expression Regulation, Fungal; Magnaporthe; Plant Diseases; Quinolones; ras Proteins; Signal Transduction; Spores, Fungal; Virulence | 2019 |
Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53.
Topics: Animals; Atorvastatin; Carcinogenesis; Cell Line, Tumor; Disease Models, Animal; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; HSP40 Heat-Shock Proteins; Humans; Mice; Molecular Chaperones; Mutant Proteins; Pancreas; Pancreatic Neoplasms; Prenylation; Proto-Oncogene Proteins p21(ras); Quinolones; Tumor Suppressor Protein p53 | 2019 |
The farnesyltransferase inhibitor tipifarnib protects against autoimmune hepatitis induced by Concanavalin A.
Topics: Animals; Antineoplastic Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Concanavalin A; Disease Models, Animal; Hepatitis, Autoimmune; Humans; Interferon-gamma; Liver; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Quinolones | 2020 |
Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.
Topics: Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Inhibitory Concentration 50; Lymphoma, T-Cell; Mutation; Phenotype; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Quinolones; Signal Transduction; T-Lymphocytes | 2020 |
Tipifarnib as a Precision Therapy for
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Head and Neck Neoplasms; Humans; Male; MAP Kinase Signaling System; Mice; Mutation; Precision Medicine; Prenylation; Proto-Oncogene Proteins p21(ras); Quinolones; Sequence Analysis, RNA; Squamous Cell Carcinoma of Head and Neck | 2020 |
Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells.
Topics: Acetophenones; Benzopyrans; Cell Line, Tumor; Cell Survival; Female; Forkhead Box Protein M1; GTP Phosphohydrolases; Humans; Membrane Proteins; Ovarian Neoplasms; Pyridines; Quinazolines; Quinolones; Signal Transduction; Thiophenes | 2021 |
Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Quinolones; Signal Transduction; Spheroids, Cellular | 2021 |
Antitumor effects of low-dose tipifarnib on the mTOR signaling pathway and reactive oxygen species production in HIF-1α-expressing gastric cancer cells.
Topics: Cell Line, Tumor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Quinolones; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases | 2021 |
Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
Topics: Animals; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Mice; Quinolones; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2021 |
Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Extracellular Vesicles; Humans; Immunologic Factors; Immunotherapy; Mice; Neuroblastoma; Quinolones; Tumor Microenvironment | 2022 |